Showing results (101-110 of 227) with videos related to
Sort By:
Pageof 23
Carcinogenesis|July 1, 1991
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometryR J Parker, I Gill, R Tarone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumorsA A Garcia, S Keren-Rosenberg, D Parimoo, et al.Seminars in Oncology|August 1, 1995
Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trialsF M Muggia, D Vafai, R Natale, et al.Cancer Investigation|January 1, 1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinomaM Turrill, D V Spicer, A S Kelley, et al.American Journal of Clinical Oncology|October 1, 1985
A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot studyK J Pandya, F M Muggia, R T Skeel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactionsA Chanan-Khan, J Szebeni, S Savay, et al.Cancer Treatment Reports|November 1, 1979
Analysis and interpretation of response rates for anticancer drugsY J Lee, R Catane, M Rozencweig, et al.Cancer|July 1, 1988
Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancerR B Weiss, D M Stablein, F M Muggia, et al.Anti-Cancer Drugs|July 19, 2001
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorinA A Garcia, F M Muggia, C P Spears, et al.Investigational New Drugs|January 1, 1986
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trialH S Hochster, M D Green, R H Blum, et al.Pageof 23